A conjugate of a dual agonist and a saccharide antigen, and methods of making and using the same
By conjugating the iNKT cell agonist KRN7000 with the mincle receptor agonist vizantin to a glycoantigen, a dual agonist-glycoantigen conjugate was constructed, which solved the problem of insufficient immunogenicity of fully synthetic tumor glycoantigen vaccines and achieved a stronger immune response and tumor cell killing effect.
CN119390739BActive Publication Date: 2026-06-19GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-14
- Publication Date
- 2026-06-19
Smart Images
Figure CN119390739B_ABST
Abstract
This invention relates to a conjugate of a dual agonist and a glycoantigen, wherein the conjugate contains a dual agonist and a glycoantigen, the dual agonist being an iNKT cell agonist and a mincle receptor agonist, the iNKT cell agonist being an α-galactosylceramide analog, and the mincle receptor agonist being a trehalose derivative; the general structural formula of the conjugate is shown in Formula (I): X is the glycoantigen, and Y is the linker. The vaccine prepared from the conjugate of this invention can simultaneously activate iNKT cells and mincle receptors, inducing the production of high-titer IgG antibodies, effectively improving the immunogenicity of the glycoantigen, and showing good prospects for anti-tumor applications.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Conjugate as well as preparation method and application thereof
CN111760020A
Trehalose derivative and carbohydrate antigen conjugate as well as preparation method and application thereof
CN111875649A